ASND vs. PFE: Ascendis Pharma vs. Pfizer Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas Ascendis Pharma (ASND) sees a more moderate 698.39K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Ascendis Pharma (ASND) at 118.78% clears its industry range for ROE, a sharper capital-efficiency signal than Pfizer (PFE) at 4.47%, which is closer to a typical peer reading.

Ascendis Pharma (ASND) at 70.85% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

Both Ascendis Pharma (ASND) at 64.98% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Pfizer (PFE) at -1.65% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.

Ascendis Pharma (ASND) at 0.31 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Ascendis Pharma (ASND) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Ascendis Pharma (ASND) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Ascendis Pharma (ASND) at 19.68 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Ascendis Pharma (ASND) at 16.14 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

Pfizer (PFE) at 1.88 is valued about in line with its industry on P/B ratio, while Ascendis Pharma (ASND) at 10.45 carries an above-peer premium to book — ASND is pricier on assets.

Valuation Metrics